Patents by Inventor Takafumi Shimizu

Takafumi Shimizu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200353488
    Abstract: Voltage application device includes voltage application circuit. Voltage application circuit applies a voltage to load including discharge electrode that holds liquid, voltage application circuit generating discharge in discharge electrode. During a drive period, voltage application circuit periodically changes a magnitude of the voltage applied to load at a drive frequency within a predetermined range including a resonance frequency of liquid, voltage application circuit mechanically vibrating liquid.
    Type: Application
    Filed: July 24, 2018
    Publication date: November 12, 2020
    Inventors: Yohei ISHIGAMI, Jumpei OE, Yukari NAKANO, Takafumi OMORI, Tetsunori AONO, Kana SHIMIZU
  • Publication number: 20200048575
    Abstract: The present invention provides a lubricating oil composition not containing ZnDTP but comprising: (a) a base oil; (b) molybdenum dialkyldithiocarbamate; and (c) an organic acid metal salt compound having a metal of Group 8 of a short periodic table, copper, or bismuth as a central metal.
    Type: Application
    Filed: March 30, 2018
    Publication date: February 13, 2020
    Applicant: Kyodo Yushi Co., Ltd.
    Inventors: Takafumi SHIMIZU, Takahiro NIHIRA
  • Patent number: 10532048
    Abstract: To provide a pharmaceutical, in particular a compound which can be used as a therapeutic agent for irritable bowel syndrome (IBS). It was found that a tetrahydroisoquinolin-1-one derivative having an amide group at the 4-position or a pharmaceutically acceptable salt thereof has an excellent bombesin 2 (BB2) receptor antagonistic action. It is also found that the tetrahydroisoquinolin-1-one derivative is highly effective on bowel movement disorders. From the above, the tetrahydroisoquinolin-1-one derivative of the present invention is useful as a therapeutic agent for diseases associated with a BB2 receptor, in particular IBS.
    Type: Grant
    Filed: July 5, 2018
    Date of Patent: January 14, 2020
    Assignee: Seldar Pharma Inc.
    Inventors: Hiroyuki Hisamichi, Itsuro Shimada, Tsukasa Ishihara, Tomofumi Takuwa, Takafumi Shimizu, Noriko Ishikawa, Kyoichi Maeno, Norio Seki
  • Publication number: 20190352472
    Abstract: In a production method for a conductive composite material for an extruder that continuously discharges a kneaded product produced by kneading a raw material using a screw, the screw has a the screw body, the raw material transported along an outer circumferential surface of the screw body receives increased pressure by a barrier part in a transport part and is introduced to a passage from an inlet, and while the kneaded product is continuously discharged, the raw material transported along the outer circumferential surface of the screw body flows in the passage of the extruder and then is guided to the transport part via an outlet provided in the screw body, the raw material contains a conductive filler and a thermoplastic elastomer.
    Type: Application
    Filed: May 15, 2019
    Publication date: November 21, 2019
    Applicants: TOSHIBA KIKAI KABUSHIKI KAISHA, HSP TECHNOLOGIES INC.
    Inventors: Takafumi SAMESHIMA, Yoshio IIZUKA, Kaho OSADA, Hiroshi SHIMIZU
  • Publication number: 20190233912
    Abstract: A steel wire for a spring is formed of a steel containing from 0.5% by mass to 0.8% by mass of carbon, from 1.0% by mass to 2.5% by mass of silicon, from 0.2% by mass to 1.0% by mass of manganese, and from 0.5% by mass to 2.5% by mass of chromium, the balance being iron and incidental impurities. The steel has a tempered martensite structure. The hardness of a surface region that is a region within 10 ?m from an outer surface is from more than 0 HV to 50 HV higher than the hardness of a region other than the surface region.
    Type: Application
    Filed: June 8, 2017
    Publication date: August 1, 2019
    Inventors: Fuminori Okada, Kenichi Shimizu, Takafumi Uwano
  • Patent number: 10301286
    Abstract: To provide a compound which can be used as an MC4 receptor agonist. The present inventors have investigated MC4 receptor agonists, and have found that a piperazine derivative has an action related to the agonists, thereby completing the present invention. That is, the piperazine derivative of the present invention has an MC4 receptor agonistic action, and can be used as an agent for preventing or treating bladder and/or urinary tract diseases, in particular, underactive bladder, hypotonic bladder, acontractile bladder, detrusor underactivity, neurogenic bladder, urethral relaxation failure, detrusor-external urethral sphincter dyssynergia, and voiding dysfunctions in benign prostatic hyperplasia.
    Type: Grant
    Filed: August 2, 2016
    Date of Patent: May 28, 2019
    Assignee: Astellas Pharma Inc.
    Inventors: Takashi Sugane, Takuya Makino, Daisuke Yamashita, Yasuhiro Yonetoku, Daisuke Tanabe, Hisashi Mihara, Norio Asai, Kazuhiko Osoda, Takafumi Shimizu, Hiroyuki Moritomo, Keizo Sugasawa, Kyoichi Maeno, Naomi Hosogai
  • Publication number: 20190000832
    Abstract: To provide a pharmaceutical, in particular a compound which can be used as a therapeutic agent for irritable bowel syndrome (IBS). It was found that a tetrahydroisoquinolin-1-one derivative having an amide group at the 4-position or a pharmaceutically acceptable salt thereof has an excellent bombesin 2 (BB2) receptor antagonistic action. It is also found that the tetrahydroisoquinolin-1-one derivative is highly effective on bowel movement disorders. From the above, the tetrahydroisoquinolin-1-one derivative of the present invention is useful as a therapeutic agent for diseases associated with a BB2 receptor, in particular IBS.
    Type: Application
    Filed: July 5, 2018
    Publication date: January 3, 2019
    Applicant: Selder Pharma Inc.
    Inventors: Hiroyuki Hisamichi, Itsuro Shimada, Tsukasa Ishihara, Tomofumi Takuwa, Takafumi Shimizu, Noriko Ishikawa, Kyoichi Maeno, Norio Seki
  • Publication number: 20180230131
    Abstract: [Problem] To provide a compound which can be used as an MC4 receptor agonist. [Means for Solution] The present inventors have investigated MC4 receptor agonists, and have found that a piperazine derivative has an action related to the agonists, thereby completing the present invention. That is, the piperazine derivative of the present invention has an MC4 receptor agonistic action, and can be used as an agent for preventing or treating bladder and/or urinary tract diseases, in particular, underactive bladder, hypotonic bladder, acontractile bladder, detrusor underactivity, neurogenic bladder, urethral relaxation failure, detrusor-external urethral sphincter dyssynergia, and voiding dysfunctions in benign prostatic hyperplasia.
    Type: Application
    Filed: August 2, 2016
    Publication date: August 16, 2018
    Applicant: Astellas Pharma Inc.
    Inventors: Takashi SUGANE, Takuya MAKINO, Daisuke YAMASHITA, Yasuhiro YONETOKU, Daisuke TANABE, Hisashi MIHARA, Norio ASAI, Kazuhiro OSODA, Takafumi SHIMIZU, Hiroyuki MORITOMO, Keizo SUGASAWA, Kyoichi MAENO, Naomi HOSAGAI
  • Patent number: 10016410
    Abstract: To provide a pharmaceutical, in particular a compound which can be used as a therapeutic agent for irritable bowel syndrome (IBS). It was found that a tetrahydroisoquinolin-1-one derivative having an amide group at the 4-position or a pharmaceutically acceptable salt thereof has an excellent bombesin 2 (BB2) receptor antagonistic action. It is also found that the tetrahydroisoquinolin-1-one derivative is highly effective on bowel movement disorders. From the above, the tetrahydroisoquinolin-1-one derivative of the present invention is useful as a therapeutic agent for diseases associated with a BB2 receptor, in particular IBS.
    Type: Grant
    Filed: November 14, 2016
    Date of Patent: July 10, 2018
    Assignee: Seldar Pharma Inc.
    Inventors: Hiroyuki Hisamichi, Itsuro Shimada, Tsukasa Ishihara, Tomofumi Takuwa, Takafumi Shimizu, Noriko Ishikawa, Kyoichi Maeno, Norio Seki
  • Publication number: 20170189390
    Abstract: To provide a pharmaceutical, in particular a compound which can be used as a therapeutic agent for irritable bowel syndrome (IBS). It was found that a tetrahydroisoquinolin-1-one derivative having an amide group at the 4-position or a pharmaceutically acceptable salt thereof has an excellent bombesin 2 (BB2) receptor antagonistic action. It is also found that the tetrahydroisoquinolin-1-one derivative is highly effective on bowel movement disorders. From the above, the tetrahydroisoquinolin-1-one derivative of the present invention is useful as a therapeutic agent for diseases associated with a BB2 receptor, in particular IBS.
    Type: Application
    Filed: November 14, 2016
    Publication date: July 6, 2017
    Applicant: Seldar Pharma Inc.
    Inventors: Hiroyuki Hisamichi, ltsuro Shimada, Tsukasa Ishihara, Tomofumi Takuwa, Takafumi Shimizu, Noriko Ishikawa, Kyoichi Maeno, Norio Seki
  • Patent number: 9637451
    Abstract: [Problem] To provide a compound useful as a MT1 and/or MT2 receptor agonist. [Solution] The present inventors have studied on MT1 and/or MT2 receptor agonists, and have confirmed that indole compounds have the activity. As a result, the present invention is accomplished. That is, a compound represented by formula (I) or a salt thereof according to the present invention has a MT1 and/or MT2 receptor agonistic activity and has a low ability of migrating into central nervous system. Therefore, the compound or a salt thereof can be used as a peripheral MT1 and/or MT2 receptor agonist, and therefore can be used as a therapeutic and/or prophylactic agent for urinary incontinence, particularly stress urinary incontinence and mixed urinary incontinence.
    Type: Grant
    Filed: January 13, 2015
    Date of Patent: May 2, 2017
    Inventors: Shunichiro Matsumoto, Takafumi Shimizu, Tomoyuki Saito, Takatoshi Kanayama, Hiroaki Tanaka, Chiharu Mori, Kazuhiro Yokoyama, Shigeo Matsui
  • Patent number: 9598434
    Abstract: Provided is a compound which is useful as an agent for treating or preventing 5-HT2C receptor-related diseases, particularly incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and the like, sexual dysfunction such as erectile dysfunction syndrome and the like, obesity, and the like. The present inventors have investigated compounds having a 5-HT2C receptor agonist activity and have found that the benzazepine compounds of the present invention have an excellent 5-HT2C receptor agonist activity, thereby completing the present invention. That is, the benzazepine compounds of the present invention have a 5-HT2C receptor agonist activity and can be used as an agent for treating or preventing 5-HT2C receptor-related diseases, particularly incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and the like, sexual dysfunction such as erectile dysfunction syndrome and the like, obesity, and the like.
    Type: Grant
    Filed: July 13, 2015
    Date of Patent: March 21, 2017
    Assignee: ASTELLAS PHARMA INC.
    Inventors: Hiroyuki Koshio, Norio Asai, Taisuke Takahashi, Takafumi Shimizu, Yasuhito Nagai, Keiko Kawabata, Karl Bruce Thor
  • Patent number: 9526719
    Abstract: To provide a pharmaceutical, in particular a compound which can be used as a therapeutic agent for irritable bowel syndrome (IBS). It was found that a tetrahydroisoquinolin-1-one derivative having an amide group at the 4-position or a pharmaceutically acceptable salt thereof has an excellent bombesin 2 (BB2) receptor antagonistic action. It is also found that the tetrahydroisoquinolin-1-one derivative is highly effective on bowel movement disorders. From the above, the tetrahydroisoquinolin-1-one derivative of the present invention is useful as a therapeutic agent for diseases associated with a BB2 receptor, in particular IBS.
    Type: Grant
    Filed: August 26, 2015
    Date of Patent: December 27, 2016
    Assignee: Seldar Pharma Inc.
    Inventors: Hiroyuki Hisamichi, Itsuro Shimada, Tsukasa Ishihara, Tomofumi Takuwa, Takafumi Shimizu, Noriko Ishikawa, Kyoichi Maeno, Norio Seki
  • Publication number: 20160332966
    Abstract: [Problem] To provide a compound useful as a MT1 and/or MT2 receptor agonist. [Solution] The present inventors have studied on MT1 and/or MT2 receptor agonists, and have confirmed that indole compounds have the activity. As a result, the present invention is accomplished. That is, a compound represented by formula (I) or a salt thereof according to the present invention has a MT1 and/or MT2 receptor agonistic activity and has a low ability of migrating into central nervous system. Therefore, the compound or a salt thereof can be used as a peripheral MT1 and/or MT2 receptor agonist, and therefore can be used as a therapeutic and/or prophylactic agent for urinary incontinence, particularly stress urinary incontinence and mixed urinary incontinence.
    Type: Application
    Filed: January 13, 2015
    Publication date: November 17, 2016
    Applicant: ASTELLAS PHARMA INC.
    Inventors: Shunichiro MATSUMOTO, Takafumi SHIMIZU, Tomoyuki SAITO, Takatoshi KANAYAMA, Hiroaki TANAKA, Chiharu MORI, Kazuhiro YOKOYAMA, Shigeo MATSUI
  • Patent number: 9376449
    Abstract: The present invention relates to indole carboxamide compounds of formula (I) or a salt thereof wherein R2, R3, R4, R6, R7, R8, R51 and R52 have the meanings as indicated herein, and are MT1 and/or MT2 receptor agonists useful for treating and/or preventing urological diseases.
    Type: Grant
    Filed: July 9, 2013
    Date of Patent: June 28, 2016
    Assignee: Astellas Pharma Inc.
    Inventors: Takatoshi Kanayama, Hideki Kubota, Shunichiro Matsumoto, Tomoyuki Saito, Takafumi Shimizu, Naoto Katoh, Shigeo Matsui
  • Patent number: 9260445
    Abstract: The present invention relates to indole carboxamide compounds of formula (I) or a salt thereof wherein R2, R3, R4, R6, R7, R8, R51 and R52 have the meanings as indicated herein, and are MT1 and/or MT2 receptor agonists useful for treating and/or preventing urological diseases.
    Type: Grant
    Filed: July 9, 2013
    Date of Patent: February 16, 2016
    Assignee: Astellas Pharma Inc.
    Inventors: Takatoshi Kanayama, Hideki Kubota, Shunichiro Matsumoto, Tomoyuki Saito, Takafumi Shimizu, Naoto Katoh, Shigeo Matsui
  • Patent number: 9256178
    Abstract: A novel power supply control device includes an external power supply unit that generates external driving power from external power source, a storing power supplying unit that generates stored driving power from stored power source, a selection unit that selects either the external driving power or the stored driving power, a power mode switching unit that switches between a normal mode and an energy saving mode that consumes less power consumption than the normal mode, a determination unit that determines whether or not current time is within a peak power shift time zone in which usage of the external power is suppressed, and a controlling unit that instructs the selection unit to select the stored power as the driving power and instructs the power mode switching unit to switch power mode to the energy saving mode immediately after finishing an operation during the power peak shift time zone.
    Type: Grant
    Filed: January 19, 2015
    Date of Patent: February 9, 2016
    Assignee: RICOH COMPANY, LTD.
    Inventor: Takafumi Shimizu
  • Publication number: 20150359787
    Abstract: To provide a pharmaceutical, in particular a compound which can be used as a therapeutic agent for irritable bowel syndrome (IBS). It was found that a tetrahydroisoquinolin-1-one derivative having an amide group at the 4-position or a pharmaceutically acceptable salt thereof has an excellent bombesin 2 (BB2) receptor antagonistic action. It is also found that the tetrahydroisoquinolin-1-one derivative is highly effective on bowel movement disorders. From the above, the tetrahydroisoquinolin-1-one derivative of the present invention is useful as a therapeutic agent for diseases associated with a BB2 receptor, in particular IBS.
    Type: Application
    Filed: August 26, 2015
    Publication date: December 17, 2015
    Applicant: Seldar Pharma Inc.
    Inventors: Hiroyuki Hisamichi, Itsuro Shimada, Tsukasa Ishihara, Tomofumi Takuwa, Takafumi Shimizu, Noriko Ishikawa, Kyoichi Maeno, Norio Seki
  • Publication number: 20150315208
    Abstract: Provided is a compound which is useful as an agent for treating or preventing 5-HT2C receptor-related diseases, particularly incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and the like, sexual dysfunction such as erectile dysfunction syndrome and the like, obesity, and the like. The present inventors have investigated compounds having a 5-HT2C receptor agonist activity and have found that the benzazepine compounds of the present invention have an excellent 5-HT2C receptor agonist activity, thereby completing the present invention. That is, the benzazepine compounds of the present invention have a 5-HT2C receptor agonist activity and can be used as an agent for treating or preventing 5-HT2C receptor-related diseases, particularly incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and the like, sexual dysfunction such as erectile dysfunction syndrome and the like, obesity, and the like.
    Type: Application
    Filed: July 13, 2015
    Publication date: November 5, 2015
    Applicant: ASTELLAS PHARMA INC.
    Inventors: Hiroyuki KOSHIO, Norio ASAI, Taisuke TAKAHASHI, Takafumi SHIMIZU, Yasuhito NAGAI, Keiko KAWABATA, Karl Bruce THOR
  • Patent number: 9157783
    Abstract: A method for producing a conductive segment, includes: a step of printing a metal conductive paste on a substrate, and drying the paste; a step of printing other metal conductive paste on the metal conductive paste after drying, and drying the paste; and a step of burning the metal conductive paste after drying and the other metal conductive paste after drying, wherein the conductive metal paste is an Ag—Pd conductive paste comprising silver (Ag) and palladium (Pd), and the other metal conductive paste is an Au conductive paste comprising gold (Au) as a main component; or the metal conductive paste is an Au conductive paste comprising gold (Au) as a main component, and the other metal conductive paste is an Ag—Pd conductive paste comprising silver (Ag) and palladium (Pd).
    Type: Grant
    Filed: July 23, 2012
    Date of Patent: October 13, 2015
    Assignee: YAZAKI CORPORATION
    Inventors: Toshio Oike, Kenichi Tanaka, Ryo Hirose, Takafumi Shimizu